Caris Life Sciences, Inc. Common Stock (CAI) Financials
Key financial figures for Caris Life Sciences, Inc. Common Stock (Q2 2026).
Caris Life Sciences, Inc. reported revenue of $263.7 million for Q2 FY2026, up 45.4% from the same period a year earlier. The company posted a net loss of $637.0 thousand, or -$0.00 per share. Operating margin came to 10.21%, against 9.92% a year earlier. Free cash flow for the period was $28.9 million. Across the last 5 reported quarters, quarterly revenue has risen from $181.4 million in Q2 FY2025 to $263.7 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Caris Life Sciences, Inc. are on the SentiSense financials page.
- Revenue
- $264M
- Net Income
- -$637K
- EPS
- $-0.00
- Total Assets
- $1.2B
- Operating Cash Flow
- $61M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $264M | -$637K | -$0.00 | 10.21% | $29M |
| Q1 FY2026 | $216M | -$510K | -$0.00 | 2.44% | $23M |
| Q4 FY2025 | $293M | $82M | $0.28 | 30.19% | $40M |
| Q3 FY2025 | $217M | $24M | $0.08 | 15.05% | $55M |
| Q2 FY2025 | $181M | -$72M | -$1.87 | 9.92% | $6M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $812M | -$538M | -$1.86 | 5.56% | $67M |
| FY2024 | $412M | -$282M | -$2.70 | -62.37% | -$254M |
| FY2023 | $306M | -$341M | -$1.82 | -104.38% | -$298M |
Frequently asked questions
What was Caris Life Sciences, Inc.'s revenue last quarter?
Caris Life Sciences, Inc. reported revenue of $263.7 million for Q2 FY2026, up 45.4% from the same period a year earlier.
Is Caris Life Sciences, Inc. profitable?
Not in its most recent reported period. Caris Life Sciences, Inc. reported a net loss of $637.0 thousand for Q2 FY2026, a net margin of -0.24% on revenue.
How has Caris Life Sciences, Inc.'s margin trended?
Operating margin was 10.21% in Q2 FY2026, compared with 9.92% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Caris Life Sciences, Inc. generate?
Caris Life Sciences, Inc. generated free cash flow of $28.9 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Caris Life Sciences, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.